Efficient multi-objective molecular optimization in a continuous latent space† †Electronic supplementary information (ESI) available: Details of the desirability scaling functions, high resolution figures and detailed results of the GuacaMol benchmark. See DOI: 10.1039/c9sc01928f
暂无分享,去创建一个
Frank Noé | Hans Briem | Floriane Montanari | Djork-Arné Clevert | Andreas Steffen | Robin Winter | Djork-Arné Clevert | F. Noé | H. Briem | Andreas Steffen | R. Winter | F. Montanari
[1] Peter Ertl,et al. Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions , 2009, J. Cheminformatics.
[2] Alexandre Varnek,et al. Estimation of the size of drug-like chemical space based on GDB-17 data , 2013, Journal of Computer-Aided Molecular Design.
[3] Suresh Babu,et al. Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS Aβ Reduction. , 2012, ACS medicinal chemistry letters.
[4] Brian K. Shoichet,et al. Virtual screening of chemical libraries , 2004, Nature.
[5] Daniel W. Davies,et al. Machine learning for molecular and materials science , 2018, Nature.
[6] Marwin H. S. Segler,et al. GuacaMol: Benchmarking Models for De Novo Molecular Design , 2018, J. Chem. Inf. Model..
[7] Jürgen Schmidhuber,et al. Deep learning in neural networks: An overview , 2014, Neural Networks.
[8] Geoffrey I. Webb,et al. Encyclopedia of Machine Learning , 2011, Encyclopedia of Machine Learning.
[9] Evgeny Putin,et al. Adversarial Threshold Neural Computer for Molecular de Novo Design. , 2018, Molecular pharmaceutics.
[10] Gaël Varoquaux,et al. Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..
[11] Markus Hartenfeller,et al. Concept of Combinatorial De Novo Design of Drug‐like Molecules by Particle Swarm Optimization , 2008, Chemical biology & drug design.
[12] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[13] Mark A. Murcko,et al. Virtual screening : an overview , 1998 .
[14] Thierry Kogej,et al. Generating Focused Molecule Libraries for Drug Discovery with Recurrent Neural Networks , 2017, ACS central science.
[15] G. V. Paolini,et al. Quantifying the chemical beauty of drugs. , 2012, Nature chemistry.
[16] Thomas Blaschke,et al. Molecular de-novo design through deep reinforcement learning , 2017, Journal of Cheminformatics.
[17] Amedeo Caflisch,et al. Fragment-Based de Novo Ligand Design by Multiobjective Evolutionary Optimization , 2008, J. Chem. Inf. Model..
[18] Geoffrey E. Hinton,et al. Deep Learning , 2015, Nature.
[19] Eduardo F. Morales,et al. An Introduction to Reinforcement Learning , 2011 .
[20] D. Cummins,et al. Integrating Everything: The Molecule Selection Toolkit, a System for Compound Prioritization in Drug Discovery. , 2016, Journal of Medicinal Chemistry.
[21] Frank Noé,et al. Learning Continuous and Data-Driven Molecular Descriptors by Translating Equivalent Chemical Representations , 2018 .
[22] Petra Schneider,et al. Multi-objective molecular de novo design by adaptive fragment prioritization. , 2014, Angewandte Chemie.
[23] Igor V. Tetko,et al. ToxAlerts: A Web Server of Structural Alerts for Toxic Chemicals and Compounds with Potential Adverse Reactions , 2012, J. Chem. Inf. Model..
[24] Esben Jannik Bjerrum,et al. Improving Chemical Autoencoder Latent Space and Molecular De Novo Generation Diversity with Heteroencoders , 2018, Biomolecules.
[25] Luhua Lai,et al. LigBuilder 2: A Practical de Novo Drug Design Approach , 2011, J. Chem. Inf. Model..
[26] Alán Aspuru-Guzik,et al. Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules , 2016, ACS central science.